Background/aim: A SARS-Cov2 infection which was first arised from Wuhan in December 2019 and named as COVID-19. Still there lacks either a specific treatment or a vaccine to treat COVID-19. Convalescent plasma (CP) was previously used successfully to treat SARS-CoV-1 and MERS infections. Health authority in Turkey has published a guideline to integrate this promising option in the treatment process of patients who are prone to high risk of developing severe COVID-19. Materials and Methods: Forty consecutive patients who had received CP at our center were included in the study. Demographics, COVID-19 specific parameters, biomarkers to detect the severity of COVID-19 infection and outcome variables were collected retrospectively. The correlation between outcome variables and the independent predictors of the outcome were reported. Results: Median age of the patients was 57.5 and 72.5% were male. At least one COVID-19 PCR test was confirmed to be positive in 75% of patients. Remaining 25% had a Chest-CT which was reported to be compatible with an ongoing COVID-19. All patients (100%) were classified as having severe COVID-19 infection. Over a half of the patients harbored an oxygen saturation of less than 90 despite of a continuous 5 L/min support of O-2. 82.5% of the patients had a need for mechanical ventilation and 45.5% had a need for invasive mechanical ventilation. Nine out of 10 patients who have received CP outside ICU have totally recovered from COVID-19 at a median of 9 days, and a half of the patients who needed invasive mechanical ventilation were successfully free of mechanical ventilation support and managed to recover from COVID-19. Conclusion: According to the results of this study, CP is an efficient conjunct to conventional therapy against COVID-19 with a favorable safety profile.
Aim: The aim of this study was to investigate the demographic characteristics of platelet apheresis donors during the coronavirus disease 2019 (COVID-19) pandemic, to examine the association of platelet counts with blood groups and body mass index (BMI), and to characterize the effects of BMI on platelet apheresis donation. Material and Methods: In this retrospective study, the demographic characteristics of platelet apheresis donors admitted to our center between January 2020 and January 2021 were examined, and hemogram parameters, previous platelet donation frequencies, and blood groups information were recorded. The relationship between donors' platelet counts, blood groups, and BMI were analyzed. Results: There was no statistically significant relationship between the platelet counts and blood groups. Although platelet counts were higher in Rh positive donors, no statistically significant relationship was found between platelet counts and the Rh group (p=0.675). Even though the platelet counts were lower in low-weight donors, there was no statistically significant relationship between platelet count and BMI groups (p=0.134). The lower collected platelet counts of the normal group, compared to the obese group, was found to be statistically significant (p=0.001). The number of donations for the overweight group being higher than the normal and obese groups was found to be statistically significant (p=0.002). Conclusion: Even though the platelet count increases with obesity, it does not have any statistical significance in healthy platelet donors. In conclusion, obesity does not have an inverse relationship with platelet apheresis donation and high BMI should not be considered as a prognostic factor for donation.
Following mass casualty disasters, blood collection activity increases in response to anticipated transfusion needs. However, this donation surge may be misaligned with clinical demands potentially increasing outdating and other forms of wastage. Evidence describing how trauma centers absorb transfusion demand while managing inventory losses in mass casuality incidents. This study evaluates changes in blood product issuance and wastage in a referral trauma center before, during, and after February 6, 2023 Kahramanmaraş Earthquake.We performed a three-year retrospective analysis of daily issue and wastage of five blood components between January 1, 2022 and December 31, 2024. Comparisons of wastage rates were made across three predefined periods (pre-earthquake, earthquake, post-earthquake), with wastage as percentage of issue calculated as aggregated estimates and weekly overalls.During the earthquake period, median daily erytrocyte suspension issuance increased by 19.7% compared with the pre-earthquake period (154 vs 127 units/day; p<0.001), without a proportional rise in expiration losses (0.2% vs 0.4%; p=0.240) . Platelet wastage decreased during the earthquake period by 7.3% for apheresis suspension, 13.9% for pooled concentrates which are consistent with faster stock turnover. In contrast, all-cause wastage of fresh frozen plasma increased across periods from 4.6% to 5.0% and 6.1% eventually.In this non-epicentral tertiary trauma center, disaster-associated increases in blood product use did not uniformly amplify wastage and were component-specific. Increased turnover during the earthquake period coincided with reduced platelet wastage, whereas fresh frozen plasmawastage rose and may reflect structural inventory factors. Period-level aggregated wastage rates provides robust benchmarking for disaster preparedness assessments especially for low-volume products.